SOURCE: Medivation

Medivation

November 23, 2011 10:00 ET

Medivation Announces Participation at Three Upcoming Investor Conferences

SAN FRANCISCO, CA--(Marketwire - Nov 23, 2011) - Medivation, Inc. (NASDAQ: MDVN) today announced that David Hung, M.D., president and chief executive officer, will present at the following three investor conferences:

  • The 23rd Annual Piper Jaffray Health Care Conference on November 30 at 2:10pm Eastern Time at the New York Palace in New York City.

  • The Deutsche Bank 2011 BioFEST Conference on December 6 at 9:10am Eastern Time at the Four Seasons Hotel in Boston, MA.

  • The Oppenheimer 22nd Annual Healthcare Conference on December 14 at 3:55pm Eastern Time at the Waldorf-Astoria Hotel in New York City.

Dr. Hung will provide an overview of Medivation and its clinical development programs.

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. Together with its corporate partners Astellas and Pfizer, Medivation currently has investigational drugs in Phase 3 development to treat advanced prostate cancer and mild-to-moderate Alzheimer's disease. For more information, please visit us at www.medivation.com.

Contact Information

  • Contacts:
    Patrick Machado
    Chief Business & Financial Officer
    (415) 829-4101

    Anne Bowdidge
    Investor Relations
    (650) 218-6900